RNA
Atrium Therapeutics, Inc.
7.90$
-0.8%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Cash Flow
Atrium Therapeutics, Inc. (RNA) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -3.9 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 11 | Q4 12 | Q1 13 | Q2 13 | Q3 13 | Q4 13 | Q1 14 | Q2 14 | Q3 14 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | -2.1 | 15 | -5.9 | -5.0 | -7.1 | -7.8 | -9.1 | -13 | -20 | -28 | -21 | -26 | -30 | -36 | -32 | -39 | -49 | -50 | -37 | 17 | -70 | -65 | -66 | -100 | -125 | -200 | -156 | -19 | -31 | -3.9 | -210 | |
| – | – | – | – | – | – | – | – | – | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.2 | 0.3 | 0.3 | 0.4 | 0.4 | 0.4 | 0.5 | 0.6 | 0.6 | 0.6 | 0.7 | 0.7 | 0.7 | 0.8 | -7.8 | 1.1 | 0.1 | 0.2 | 0.3 | 1.7 | |
| – | – | – | – | – | – | – | – | – | 0.0 | 0.0 | 0.0 | 0.4 | 0.4 | 0.7 | 1.3 | 1.9 | 3.7 | 4.3 | 4.6 | 4.5 | 6.2 | 6.5 | 7.1 | 7.3 | 9.1 | 9.5 | 9.8 | 9.8 | 10 | 13 | 14 | 14 | 18 | 18 | 19 | 3.6 | 12 | 0.9 | 36 | |
| – | – | – | – | – | – | – | – | – | 0.4 | 1.1 | 1.4 | – | 0.5 | 0.8 | 1.3 | 1.9 | 3.7 | 4.3 | 4.6 | 4.6 | 6.4 | 6.6 | 7.0 | 6.5 | 7.3 | 7.3 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | 0.0 | 19 | -0.7 | 0.4 | -1.6 | 1.8 | 0.9 | 1.2 | 0.3 | -6.2 | 3.7 | 7.5 | -2.7 | 2.6 | 4.2 | 4.4 | -4.5 | -11 | 7.4 | 69 | -10 | -4.1 | 6.0 | -6.2 | -23 | -58 | -0.5 | 5.8 | -28 | 15 | -8.0 | |
| 2.6 | 0.3 | 0.3 | 0.5 | 0.6 | 0.8 | 0.1 | 0.5 | 0.6 | 0.0 | 0.1 | 0.0 | 0.1 | 0.0 | 0.8 | 0.8 | 0.2 | 0.5 | 0.7 | 0.8 | 1.7 | 0.8 | 1.3 | 0.1 | 0.9 | 1.8 | 0.6 | 0.9 | 0.9 | 0.9 | 0.5 | 1.7 | 3.9 | 3.8 | 3.3 | 3.9 | 0.9 | 2.1 | 0.0 | 6.9 | |
| – | – | – | – | – | – | – | – | – | -0.1 | -0.1 | 0.0 | -0.1 | 0.0 | -0.8 | -0.8 | -6.9 | -0.5 | 2.9 | -0.8 | -84 | -175 | -18 | 11 | -7.8 | -196 | 46 | -31 | 51 | -33 | -275 | -482 | -64 | 157 | 185 | -588 | -0.9 | -2.1 | -192 | -782 | |
| – | – | – | – | – | – | – | – | – | 0.0 | – | – | 0.1 | 0.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | 0.0 | – | 0.0 | 73 | 2.2 | – | – | 0.4 | – | – | – | 0.7 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | 3.8 | 14 | -0.7 | – | -0.7 | -4.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.6 | 34 | – | 0.7 | 86 | 88 | 0.1 | – | 0.4 | 3.8 | 14 | -0.7 | 72 | 1.3 | 272 | -1.3 | 0.5 | 0.0 | 0.4 | 155 | 21 | 24 | 39 | 40 | 244 | 23 | 39 | 0.0 | 32 | 389 | 447 | 342 | 14 | 1.9 | 3.8 | 850 | 20 | 302 | 0.0 | 1,172 | |
| – | – | – | – | – | – | – | – | – | 1.7 | 30 | -6.6 | 67 | -5.8 | 264 | -11 | -20 | -20 | -25 | 134 | -90 | -181 | -14 | 19 | 197 | -222 | 35 | -68 | 99 | 286 | 107 | -206 | -150 | 34 | -10 | 106 | 32 | 268 | -195 | 211 | |
| – | – | – | – | – | – | – | – | – | -2.1 | 15 | -5.9 | -5.1 | -7.2 | -7.8 | -10.0 | -13 | -20 | -29 | -22 | -28 | -30 | -37 | -32 | -40 | -51 | -50 | -38 | 16 | -71 | -66 | -67 | -104 | -129 | -203 | -160 | -20 | -33 | -4.0 | -217 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.